首頁 > 市場調查報告書 > 製藥

呼吸器

市場調查報告書

商品編碼

1820632

全球口服祛痰藥市場研究報告 - 產業分析、規模、佔有率、成長、趨勢及預測（2025 年至 2033 年）

Global Oral Expectorant Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

出版日期: 2025年07月01日 | 出版商:

Value Market Research | 英文 143 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球口服祛痰藥市場預測將大幅成長，預計到 2033 年市場規模將飆升至 67.8 億美元，較 2024 年的 49 億美元大幅成長。這一擴張反映了 2025 年至 2033 年期間預計 3.68% 的驚人年複合成長率(CAGR)。

受支氣管炎、慢性阻塞性肺病 (COPD) 和普通感冒等呼吸系統疾病日益流行的推動，全球口服祛痰藥市場有望穩步成長。祛痰藥有助於清除黏液，改善呼吸功能，提升患者舒適度。未來的發展將著重於研發療效更佳、副作用更少、天然成分更豐富的新型製劑。

此外，空氣污染和吸菸率的上升加劇了呼吸系統健康挑戰，擴大了市場需求。非處方藥 (OTC) 的成長和自我藥療趨勢正在擴大消費者的可近性。包括緩釋和聯合療法在內的藥物傳輸技術的進步正在改善治療效果。隨著呼吸照護的發展，口服祛痰藥市場將持續創新，提供安全、有效且病人友善的解決方案。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美各細分市場銷售分析
- 北美各國銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲各細分市場銷售分析
- 歐洲各國銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區分部銷售分析
- 亞太地區國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲各細分市場銷售分析
- 拉丁美洲各國銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲分部銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東和非洲其他地區銷售分析

第 10 章：口服祛痰藥公司的競爭格局

口服祛痰藥市場競爭
夥伴關係/合作/協議
併購
新產品發布
其他發展

第 11 章：公司簡介

頂級公司市佔率分析
市場集中度
Abbott Laboratories

公司概況
公司收入
產品
最新動態

AstraZeneca

公司概況
公司收入
產品
最新動態

Cipla Inc.

公司概況
公司收入
產品
最新動態

Genexa Inc.

公司概況
公司收入
產品
最新動態

GlaxoSmithKline (GSK) Plc

公司概況
公司收入
產品
最新動態

Merck KGaA

公司概況
公司收入
產品
最新動態

Perrigo Company Plc

公司概況
公司收入
產品
最新動態

Reckitt Benckiser Group PLC

公司概況
公司收入
產品
最新動態

Sanofi

公司概況
公司收入
產品
最新動態

Sun Pharmaceutical Industries Ltd.

公司概況
公司收入
產品
最新動態

The Himalaya Drug Company

公司概況
公司收入
產品
最新動態

注意 - 在公司簡介中，財務細節和最新發展取決於可用性，或者在私人公司的情況下可能不涵蓋

簡介目錄圖表

Product Code: VMR112114265

The forecast for the global Oral Expectorant market predicts substantial growth, with market size projected to soar to USD 6.78 Billion by 2033, a significant increase from the USD 4.9 Billion recorded in 2024. This expansion reflects an impressive compound annual growth rate (CAGR) of 3.68% anticipated between 2025 and 2033.

The global oral expectorant market is set for steady growth driven by increasing prevalence of respiratory diseases such as bronchitis, chronic obstructive pulmonary disease (COPD), and common cold. Expectorants facilitate mucus clearance, improving respiratory function and patient comfort. Future developments will focus on novel formulations with enhanced efficacy, reduced side effects, and natural ingredient integration.

Additionally, rising air pollution and smoking rates are contributing to respiratory health challenges, expanding market demand. The growth of over-the-counter (OTC) products and self-medication trends is broadening consumer access. Advances in drug delivery technologies, including sustained-release and combination therapies, are improving treatment outcomes. As respiratory care evolves, the oral expectorant market will continue to innovate, delivering safe, effective, and patient-friendly solutions.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

LIST OF SEGMENTS COVERED

This section of the Oral Expectorant market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Type

Secretion Enhancer
Mucolytics

By Dosage Form

Oral Solids
Oral Liquids
Inhalants

By Medication

Prescription Drugs
Over-The-Counter Drugs

By Distribution Channel

Hospital Pharmacies
Retail Store & Drug Store
List of Companies Profiled in the report
Abbott Laboratories, AstraZeneca, Cipla Inc., Genexa Inc., GlaxoSmithKline (GSK) plc, Merck KGaA, Perrigo Company plc, Reckitt Benckiser Group PLC, Sanofi, Sun Pharmaceutical Industries Ltd., The Himalaya Drug Company.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. ORAL EXPECTORANT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Type
- 3.7.2 Market Attractiveness Analysis By Dosage Form
- 3.7.3 Market Attractiveness Analysis By Medication
- 3.7.4 Market Attractiveness Analysis By Distribution Channel
- 3.7.5 Market Attractiveness Analysis By Regions

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL ORAL EXPECTORANT MARKET ANALYSIS BY DRUG TYPE

5.1. Overview By Drug Type
5.2. Historical and Forecast Data Analysis By Drug Type
5.3. Secretion Enhancer Historic and Forecast Sales By Regions
5.4. Mucolytics Historic and Forecast Sales By Regions

6. GLOBAL ORAL EXPECTORANT MARKET ANALYSIS BY DOSAGE FORM

6.1. Overview By Dosage Form
6.2. Historical and Forecast Data Analysis By Dosage Form
6.3. Oral Solids Historic and Forecast Sales By Regions
6.4. Oral Liquids Historic and Forecast Sales By Regions
6.5. Inhalants Historic and Forecast Sales By Regions

7. GLOBAL ORAL EXPECTORANT MARKET ANALYSIS BY MEDICATION

7.1. Overview By Medication
7.2. Historical and Forecast Data Analysis By Medication
7.3. Prescription Drugs Historic and Forecast Sales By Regions
7.4. Over-The-Counter Drugs Historic and Forecast Sales By Regions

8. GLOBAL ORAL EXPECTORANT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

8.1. Overview By Distribution Channel
8.2. Historical and Forecast Data Analysis By Distribution Channel
8.3. Hospital Pharmacies Historic and Forecast Sales By Regions
8.4. Retail Store & Drug Store Historic and Forecast Sales By Regions

9. GLOBAL ORAL EXPECTORANT MARKET ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook
9.2. Introduction
9.3. North America Sales Analysis
- 9.3.1 Overview, Historic and Forecast Data Sales Analysis
- 9.3.2 North America By Segment Sales Analysis
- 9.3.3 North America By Country Sales Analysis
- 9.3.4 United States Sales Analysis
- 9.3.5 Canada Sales Analysis
- 9.3.6 Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1 Overview, Historic and Forecast Data Sales Analysis
- 9.4.2 Europe By Segment Sales Analysis
- 9.4.3 Europe By Country Sales Analysis
- 9.4.4 United Kingdom Sales Analysis
- 9.4.5 France Sales Analysis
- 9.4.6 Germany Sales Analysis
- 9.4.7 Italy Sales Analysis
- 9.4.8 Russia Sales Analysis
- 9.4.9 Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1 Overview, Historic and Forecast Data Sales Analysis
- 9.5.2 Asia Pacific By Segment Sales Analysis
- 9.5.3 Asia Pacific By Country Sales Analysis
- 9.5.4 China Sales Analysis
- 9.5.5 India Sales Analysis
- 9.5.6 Japan Sales Analysis
- 9.5.7 South Korea Sales Analysis
- 9.5.8 Australia Sales Analysis
- 9.5.9 South East Asia Sales Analysis
- 9.5.10 Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1 Overview, Historic and Forecast Data Sales Analysis
- 9.6.2 Latin America By Segment Sales Analysis
- 9.6.3 Latin America By Country Sales Analysis
- 9.6.4 Brazil Sales Analysis
- 9.6.5 Argentina Sales Analysis
- 9.6.6 Peru Sales Analysis
- 9.6.7 Chile Sales Analysis
- 9.6.8 Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1 Overview, Historic and Forecast Data Sales Analysis
- 9.7.2 Middle East & Africa By Segment Sales Analysis
- 9.7.3 Middle East & Africa By Country Sales Analysis
- 9.7.4 Saudi Arabia Sales Analysis
- 9.7.5 UAE Sales Analysis
- 9.7.6 Israel Sales Analysis
- 9.7.7 South Africa Sales Analysis
- 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE ORAL EXPECTORANT COMPANIES

10.1. Oral Expectorant Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11. COMPANY PROFILES OF ORAL EXPECTORANT INDUSTRY

11.1. Top Companies Market Share Analysis
11.2. Market Concentration Rate
11.3. Abbott Laboratories
- 11.3.1 Company Overview
- 11.3.2 Company Revenue
- 11.3.3 Products
- 11.3.4 Recent Developments
11.4. AstraZeneca
- 11.4.1 Company Overview
- 11.4.2 Company Revenue
- 11.4.3 Products
- 11.4.4 Recent Developments
11.5. Cipla Inc.
- 11.5.1 Company Overview
- 11.5.2 Company Revenue
- 11.5.3 Products
- 11.5.4 Recent Developments
11.6. Genexa Inc.
- 11.6.1 Company Overview
- 11.6.2 Company Revenue
- 11.6.3 Products
- 11.6.4 Recent Developments
11.7. GlaxoSmithKline (GSK) Plc
- 11.7.1 Company Overview
- 11.7.2 Company Revenue
- 11.7.3 Products
- 11.7.4 Recent Developments
11.8. Merck KGaA
- 11.8.1 Company Overview
- 11.8.2 Company Revenue
- 11.8.3 Products
- 11.8.4 Recent Developments
11.9. Perrigo Company Plc
- 11.9.1 Company Overview
- 11.9.2 Company Revenue
- 11.9.3 Products
- 11.9.4 Recent Developments
11.10. Reckitt Benckiser Group PLC
- 11.10.1 Company Overview
- 11.10.2 Company Revenue
- 11.10.3 Products
- 11.10.4 Recent Developments
11.11. Sanofi
- 11.11.1 Company Overview
- 11.11.2 Company Revenue
- 11.11.3 Products
- 11.11.4 Recent Developments
11.12. Sun Pharmaceutical Industries Ltd.
- 11.12.1 Company Overview
- 11.12.2 Company Revenue
- 11.12.3 Products
- 11.12.4 Recent Developments
11.13. The Himalaya Drug Company
- 11.13.1 Company Overview
- 11.13.2 Company Revenue
- 11.13.3 Products
- 11.13.4 Recent Developments